Showing 1401-1410 of 1576 results for "".
- J&J Launches Daily Disposable Multifocal Toric Contact Lens: Acuvue Oasys Max 1-Day Multifocal for Astigmatismhttps://modernod.com/news/johnson-johnson-launches-daily-disposable-multifocal-toric-contact-lens-acuvue-oasys-max-1-day-multifocal-for-astigmatism/2482858/Johnson & Johnson announced the launch of Acuvue Oasys Max 1-Day Multifocal for Astigmatism, a daily disposable contact lens for people with both astigmatism and presbyopia. The company says this contact lens provides patients crisp, clear, stable vision at all distances and in all
- Ocular Therapeutix To Close Enrollment this Week for SOL-R Trial Evaluating Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-to-close-enrollment-this-week-for-sol-r-trial-evaluating-axpaxli-in-wet-amd/2482822/Ocular Therapeutix announced that enrollment in the SOL-R registrational trial of its product candidate Axpaxli in wet age-related macular degeneration (AMD) will close this week. “Completing enrollment in SOL-R—the largest retinal TKI trial to date—one year
- CE-Mark Granted to deepeye Medical for AI Tool for Retinal Therapy Planninghttps://modernod.com/news/ce-mark-granted-to-deepeye-medical-for-ai-tool-for-retinal-therapy-planning/2482816/deepeye Medical has received CE Mark for its deepeye TPS¹ (Therapy Planning Support) platform. The Class IIa approval was made under the EU Medical Device Regulation (MDR 2017/745), following certification by the Notified Body
- Ace Vision Group Closes $29.4 Million Series B Financing Roundhttps://modernod.com/news/ace-vision-group-closes-294-million-series-b-financing-round/2482767/Ace Vision Group announced the successful close of a $29.4 million Series B financing round. The new capital will support the continued development of the company’s proprietary Gen II VisioLite Ophthalmic Laser, which delivers the minimally invasive LSM procedure—a treatment targ
- Opthea Discontinues Wet AMD Trials After Another Failed Phase 3 Trialhttps://modernod.com/news/opthea-discontinues-wet-amd-trials-after-another-failed-phase-3-trial/2482721/Just a week after Opthea announced that its combination drug candidate—2 mg sozinibercept combined with 2 mg aflibercept—did not meet its primary endpoint in the COAST phase 3 trial, the company announced similar results with its phase 3 ShORe (Study of OPT-302 in
- Opus Genetics Presents Phentolamine Ophthalmic Solution 0.75% Improves Visual Acuity in Patients with Dim Light Disturbances, World Cornea Congress IXhttps://modernod.com/news/opus-genetics-presents-phentolamine-ophthalmic-solution-075-improves-visual-acuity-in-patients-with-dim-light-disturbances-world-cornea-congress-ix/2482711/Opus Genetics, Inc. shared the positive findings of their Phentolamine Ophthalmic Solution 0.75% to improve visual acuity in patients with dim light disturbances last week at the World Cornea Congress IX in Washington D.C. The results are from the company’s LYNX-1 phase 3 cli
- TECLens Secures $9.3 Million Series A Funding to Advance Its Noninvasive Refractive Technologyhttps://modernod.com/news/teclens-secures-93-million-series-a-funding-to-advance-its-noninvasive-refractive-technology/2482658/TECLens announced it raised $9.3 million in a Series A round to support the clinical development of the company’s non-incisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. The funding round was co-led by Johnson &
- Specialty Contact Lens Division WAVE Eye Care Formedhttps://modernod.com/news/specialty-contact-lens-division-wave-eye-care-formed/2482616/EyePrint Prosthetics, Advanced Vision Technologies (AVT), and WAVE Contact Lens System—three providers of specialty contact lens fitting—have united to form WAVE Eye Care, a division dedicated to providing fully customized specialty contact lenses. According to a j
- CellViva Appoints Three Ophthalmology Leaders to Board of Directorshttps://modernod.com/news/cellviva-appoints-three-ophthalmology-leaders-to-board-of-directors/2482577/CellViva, a biopharmaceutical company developing anti-vascular endothelial growth factor—anti-VEGF—therapy for pterygium, announced the appointment of three leaders in ophthalmology to its Board of Directors. According to CellViva, the new directors are: Ad
- Bausch + Lomb’s Recycling Programs Collect Over 94 Million Units of Eye Care Waste in the UShttps://modernod.com/news/bausch-lombs-recycling-programs-collect-over-94-million-units-of-eye-care-waste-in-the-us/2482541/Bausch + Lomb announced a milestone in its sustainability efforts—the company's exclusive recycling initiatives, ONE by ONE Recycling and Biotrue Eye Care Recycling programs, have successfully collected a total of 94,119,275 units of used contact lenses, eye care, and lens care material